FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091864171> ?p ?o ?g. }

• W2091864171 endingPage "457" @default.
• W2091864171 startingPage "453" @default.
• W2091864171 abstract "Purpose: Studies evaluating the relationship of HER-2/neu breast tumor status and response to adjuvant endocrine therapy have reached conflicting conclusions about resistance of HER-2/neu-positive tumors to this treatment. We studied 282 patients participating in a randomized controlled trial of adjuvant oophorectomy and tamoxifen or observation who had estrogen receptor-positive tumors and whose tumors were evaluated for HER-2/neu overexpression by immunohistochemistry. Patients and Methods: Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier disease-free and overall survival estimate methods were used. Results: HER-2/neu overexpression was a negative prognostic factor for overall survival. In univariate analyses, in HER-2/neu-positive patients, the hazard ratio (HR) for disease-free survival (DFS) with adjuvant endocrine therapy was 0.37 (95% confidence interval [CI], 0.26 to 0.89); for HER-2/neu-negative patients, the corresponding HR for DFS was 0.48 (95% CI, 0.31 to 0.71). The overall survival (OS) data were HR=0.26 (95% CI, 0.07 to 0.92) and HR=0.68 (95% CI, 0.32 to 1.42) for HER-2/neu-positive and HER-2/neu-negative patients, respectively. In multivariate models, the P values for tests of interaction of HER-2/neu status and response to adjuvant endocrine therapy were 0.18 and 0.07 for DFS and OS, respectively. Kaplan-Meier DFS and OS curves and 3-year DFS estimates were consistent in showing greater benefit to the HER-2/neu-positive subgroup given adjuvant treatment. Conclusion: HER-2/neu overexpression does not adversely and may favorably influence response to adjuvant oophorectomy and tamoxifen treatment in patients with estrogen receptor–positive tumors." @default.
• W2091864171 created "2016-06-24" @default.
• W2091864171 creator A5027087179 @default.
• W2091864171 creator A5034779816 @default.
• W2091864171 creator A5043145789 @default.
• W2091864171 creator A5049652855 @default.
• W2091864171 creator A5052441498 @default.
• W2091864171 creator A5054126048 @default.
• W2091864171 creator A5057968330 @default.
• W2091864171 date "2003-02-01" @default.
• W2091864171 modified "2023-10-16" @default.
• W2091864171 title "HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer" @default.
• W2091864171 cites W1562190372 @default.
• W2091864171 cites W1820219315 @default.
• W2091864171 cites W1919384911 @default.
• W2091864171 cites W1919801416 @default.
• W2091864171 cites W1925485320 @default.
• W2091864171 cites W1932878073 @default.
• W2091864171 cites W1988985184 @default.
• W2091864171 cites W2040077715 @default.
• W2091864171 cites W2062713892 @default.
• W2091864171 cites W2073760973 @default.
• W2091864171 cites W2101577390 @default.
• W2091864171 cites W2110442763 @default.
• W2091864171 cites W2114167623 @default.
• W2091864171 cites W2146587811 @default.
• W2091864171 cites W2151128729 @default.
• W2091864171 cites W2343407300 @default.
• W2091864171 cites W3147894994 @default.
• W2091864171 cites W4293241248 @default.
• W2091864171 doi "https://doi.org/10.1200/jco.2003.10.133" @default.
• W2091864171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12560434" @default.
• W2091864171 hasPublicationYear "2003" @default.
• W2091864171 type Work @default.
• W2091864171 sameAs 2091864171 @default.
• W2091864171 citedByCount "121" @default.
• W2091864171 countsByYear W20918641712012 @default.
• W2091864171 countsByYear W20918641712013 @default.
• W2091864171 countsByYear W20918641712014 @default.
• W2091864171 countsByYear W20918641712015 @default.
• W2091864171 countsByYear W20918641712016 @default.
• W2091864171 countsByYear W20918641712017 @default.
• W2091864171 countsByYear W20918641712018 @default.
• W2091864171 countsByYear W20918641712019 @default.
• W2091864171 countsByYear W20918641712020 @default.
• W2091864171 countsByYear W20918641712021 @default.
• W2091864171 countsByYear W20918641712022 @default.
• W2091864171 crossrefType "journal-article" @default.
• W2091864171 hasAuthorship W2091864171A5027087179 @default.
• W2091864171 hasAuthorship W2091864171A5034779816 @default.
• W2091864171 hasAuthorship W2091864171A5043145789 @default.
• W2091864171 hasAuthorship W2091864171A5049652855 @default.
• W2091864171 hasAuthorship W2091864171A5052441498 @default.
• W2091864171 hasAuthorship W2091864171A5054126048 @default.
• W2091864171 hasAuthorship W2091864171A5057968330 @default.
• W2091864171 hasConcept C121608353 @default.
• W2091864171 hasConcept C126322002 @default.
• W2091864171 hasConcept C143998085 @default.
• W2091864171 hasConcept C144301174 @default.
• W2091864171 hasConcept C207103383 @default.
• W2091864171 hasConcept C2777176818 @default.
• W2091864171 hasConcept C2777863537 @default.
• W2091864171 hasConcept C2777982462 @default.
• W2091864171 hasConcept C29456083 @default.
• W2091864171 hasConcept C38180746 @default.
• W2091864171 hasConcept C44249647 @default.
• W2091864171 hasConcept C50382708 @default.
• W2091864171 hasConcept C530470458 @default.
• W2091864171 hasConcept C71924100 @default.
• W2091864171 hasConcept C84606932 @default.
• W2091864171 hasConceptScore W2091864171C121608353 @default.
• W2091864171 hasConceptScore W2091864171C126322002 @default.
• W2091864171 hasConceptScore W2091864171C143998085 @default.
• W2091864171 hasConceptScore W2091864171C144301174 @default.
• W2091864171 hasConceptScore W2091864171C207103383 @default.
• W2091864171 hasConceptScore W2091864171C2777176818 @default.
• W2091864171 hasConceptScore W2091864171C2777863537 @default.
• W2091864171 hasConceptScore W2091864171C2777982462 @default.
• W2091864171 hasConceptScore W2091864171C29456083 @default.
• W2091864171 hasConceptScore W2091864171C38180746 @default.
• W2091864171 hasConceptScore W2091864171C44249647 @default.
• W2091864171 hasConceptScore W2091864171C50382708 @default.
• W2091864171 hasConceptScore W2091864171C530470458 @default.
• W2091864171 hasConceptScore W2091864171C71924100 @default.
• W2091864171 hasConceptScore W2091864171C84606932 @default.
• W2091864171 hasIssue "3" @default.
• W2091864171 hasLocation W20918641711 @default.
• W2091864171 hasLocation W20918641712 @default.
• W2091864171 hasOpenAccess W2091864171 @default.
• W2091864171 hasPrimaryLocation W20918641711 @default.
• W2091864171 hasRelatedWork W2034033931 @default.
• W2091864171 hasRelatedWork W2049746519 @default.
• W2091864171 hasRelatedWork W2062795632 @default.
• W2091864171 hasRelatedWork W2111940104 @default.
• W2091864171 hasRelatedWork W2149921346 @default.
• W2091864171 hasRelatedWork W2151206172 @default.
• W2091864171 hasRelatedWork W2166631738 @default.
• W2091864171 hasRelatedWork W2327258659 @default.

• next